Wegovy, other weight-loss drugs might help with alcoholism, opioid addiction
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
Weight-Loss Meds Like Wegovy Could Battle Alcoholism
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1),
Weight loss drugs could help with alcohol, opioid addiction, study says
Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.
Ozempic: Weight Loss Drug May Help With Addiction Too
These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.
Weight loss drugs may help reduce drug and alcohol misuse: Research
Weight loss medications such as Ozempic may be able to cut drug and alcohol misuse in half, according to a new study from the scientific journal Addiction. The research, published Thursday, found that people who take Ozempic or similar drugs — those used for weight loss or treating Type 2 diabetes — were 40
ConsumerAffairs21h
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
This is Huge News For Eli Lilly Investors
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
The Crackdown on Compounded GLP-1 Meds Has Begun
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
2 High-Flying Growth Stocks With Massive Upside Potential
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
pharmaphorum13d
Mounjaro and Zepbound shortages over, declares FDA
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...